Avoca Quality Consortium 2013 Summit Breaking Down Silos

Avoca Quality Consortium 2013 Summit

Sponsored by Eli Lilly and Company and Pfizer, Inc., The Avoca Quality
Consortium brings together quality, outsourcing and operational
professionals from Member pharma, biotech and CRO organizations to
accelerate the development of best practices and industry standards for
proactive quality management.
THANK YOU TO OUR
CONSORTIUM SPONSORS
AVOCA QUALITY CONSORTIUM CORE TENETS:
• Objective Research: Providing insights to individual companies and
setting Quality Consortium priorities
• Leading Practices: Optimizing approaches to proactive quality
management
• Collaboration: Pharma companies, biotech companies, and CROs
working together to achieve common goals
• Engagement: Member involvement at the Executive as well as Functional
level; engagement with regulatory authorities to strive for mutual
understanding and acknowledgement
• Transparency: Sharing of information with other groups, organizations,
and industry consortia to ensure no duplication of efforts
• Implementation: Operationalizing approaches to proactive quality
management
• Innovation: Focusing the Quality Consortium’s future priorities on
“out-of-the-box” approaches; leading the way for industry breakthroughs

PATRICIA LEUCHTEN
President & CEO - The Avoca Group, Inc.
WELCOME
On behalf of The Avoca Group – as well as our Co-Chairs, John Hubbard and
Jeffrey Kasher, and our Summit Sponsor, Stephen Cutler -- welcome to the 2014
Avoca Quality Consortium Summit!
I want to offer a special welcome to the new Sponsor and CRO Member
companies who have chosen to join us this year, including: Baxter Healthcare,
Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Premier Research and
TAKE Solutions. I thank you, as well as our many longstanding Members, for
believing in the importance of collaboration through the Quality Consortium.
Since we founded the Quality Consortium in early 2012, we have experienced
steady growth. I am especially pleased to see that many of the original initiatives have begun to take hold.
Using the 2012 Quality Agreement template as a key component, we moved into a robust, eight component
framework for effective oversight. Additionally, insights into Quality Metrics that began in 2012 resulted in a
new taxonomy and framework for metrics.
As the Quality Consortium continues to grow and take on new initiatives in the advancement of quality in
clinical trials, it is important that we remain committed to the Core Tenets established by our original Members
in 2012.
The original vision of the Avoca Quality Consortium was to help individual companies optimize their
approaches to proactive quality management, while focusing on a larger vision to move toward standards for
quality management. While this remains the core of the Quality Consortium, we feel an obligation in 2014 and
beyond to help transform clinical trial execution as a way to improve overall quality.
The theme and focus for this year’s Avoca Quality Consortium Summit reinforces that objective: Breaking
Down Silos, Advancing Technology and Building Bridges to Patients. Our guest speakers and panel topics
promise an exciting exchange centered around these themes. Our Quality Consortium gatherings -- and the
Summit in particular – are all about creating an environment where new ideas can emerge from an open
exchange of information.
In keeping with this, we have developed a program that addresses our industry’s need for transformation,
particularly in the way companies work together, their ability to leverage information and technology, and
through Sponsor and CRO relationships with sites and patients.
One important initiative the Quality Consortium launched this year was in fact borne out of a debate held at
our very first Avoca Quality Consortium Summit. You’ll hear more over the coming two days about how we
propose to transform the approach the industry takes to the prequalification of suppliers in order to reduce
costs and increase efficiency for all stakeholders.
As always, this meeting would not be possible without the support of our Summit Sponsors. With special
recognition to our leading sponsor ICON Clinical Research, I want to thank everyone who continues to believe
in our work and this important industry movement including: Acurian, Inc., DrugDev, INC Research, and inVentiv
Health Clinical.
I look forward to spending time with you at this third annual Avoca Quality Consortium Summit!
Warm regards,

4 Avoca Quality Consortium 2014 Summit
SUMMIT CO-CHAIRS
Eli Lilly and Company
Jeffrey S. Kasher, Ph.D., was named Vice President, Global Clinical Innovation and
Implementation in September 2012. In his current role Jeff has the opportunity to
lead significant, disruptive, Patient Centric Transformational efforts in the company
and ensure delivery of the innovative molecules that are currently in Lilly’s clinical
portfolio.
Dr. Kasher received a Bachelor of Science degree in chemistry from Franklin &
Marshall College (Lancaster, Pa), a doctorate in pharmacology from the State
University of New York (Syracuse) and a postdoctoral fellowship in physiology at
Yale University School of Medicine.
Jeffrey S. Kasher, Ph.D.
Dr. Hubbard is Senior Vice President and Worldwide Head of Development
Operations for Pfizer Inc. In this position, he is responsible for clinical trial
operations and management of more than 450 clinical projects from Phase I to
IV. Dr. Hubbard serves as Co-Chair of Pfizer’s early Development Committee and
Clinical and Medical Excellence Innovation Board and is a member of the Portfolio
Strategy and Investment Committee and Worldwide Research & Development
Leadership Team.

Dr. Hubbard received a Bachelor of Science degree in Biopsychology from the
University of Santa Clara and a Doctorate from the University of Tennessee, with a
research focus on the genetic basis of hypertension and autonomic dysfunction.
He was a National Institute of Health Postdoctoral Fellow in Cardiovascular and
Clinical Pharmacology at the University of Texas Health Sciences Center.
Pfizer, Inc.
John W. Hubbard, Ph.D., FCP

5Avoca Quality Consortium 2014 Summit
KEYNOTE SPEAKER
Jamie Heywood
An MIT-trained mechanical engineer, Jamie entered the field of translational medicine
when his 29 year old brother Stephen was diagnosed with ALS, or Lou Gehrig’s
Disease. Today, Heywood is the chairman of PatientsLikeMe, where he provides the
scientific vision and architecture for its patient-centered medical platform. He
co-founded the company in 2004 with his youngest brother, Benjamin, and friend,
Jeff Cole.
Named one of “15 companies that will change the world” by CNN Money,
PatientsLikeMe is a personalized research and peer care platform that allows patients
to share in-depth information on treatments, symptoms and outcomes. This novel
open model allows clinicians, providers and the pharmaceutical industry to better
understand diseases and the patient experience. Patients improve their care while
actively partnering with industry to accelerate and influence the development of new
treatments and biomarkers.
Jamie is also the founder and past CEO of the ALS Therapy Development Institute
(ALS TDI), the world’s first non-profit biotechnology company. During his tenure at
ALS TDI Jamie helped pioneer an open research model and industrialized therapeutic
validation process that made ALS TDI the world’s largest and most comprehensive
ALS research program.
Heywood’s work has been profiled in the The New Yorker, The New York Times
Magazine, Businessweek, 60 Minutes, CBS Evening News, NPR, Science, and Nature. In
2009, he was chosen for WIRED magazine’s “Smart List” and Fast Company’s
“10 Most Creative People in Healthcare.” Heywood and his brother Stephen were the
subjects of Pulitzer Prize winner Jonathan Wiener’s biography, His Brother’s Keeper,
and the Sundance award-winning documentary, “So Much So Fast.”
Co-Founder, Chairman
PatientsLikeMe

EXECUTIVE ROUNDTABLE
PANELISTS AND PRESENTERS
Peter Aurup, M.D.
Merck Research Laboratories
Peter Aurup, M.D., is Vice President and Head of Global Clinical Trial Operations
(GCTO) at Merck Research Laboratories. In this role, he is responsible for all
aspects of clinical trial execution including data management for all global, regional
and local studies in all of Merck’s therapeutic areas. Dr. Aurup leads a function of
approximately 3,800 people, with locations in the U.S. and abroad. Currently, there
are approximately 275,000 patients participating in Merck/MSD sponsored clinical
trial programs worldwide.
Dr. Aurup received his medical degree from the Medical School at University of
Copenhagen, Denmark, in 1983 and worked in internal medicine and cardiology
before joining the pharmaceutical industry in 1988.
Dr. Cutler has 24 years of experience within the pharmaceutical and CRO industry
and joined ICON plc from Kendle where he held the position of Chief Executive
Officer, having previously served as Kendle’s Chief Operating Officer. Prior to
Kendle, Steve spent 14 years with Quintiles where he served as Senior Vice
President, Global Project Management; Senior Vice President, Clinical, Medical
and Regulatory; Senior Vice President, Project Management - Europe; and Vice
President, Oncology - Europe as well as regional leadership positions in South
Africa and Australia. Prior to joining Quintiles, Steve held positions with Sandoz
(now Novartis) in Australia and Europe. He holds a B.Sc. and a PhD from the
University of Sydney and a Masters of Business Administration from the
University of Birmingham (UK).
ICON plc
Stephen Cutler, Ph.D.

Coleen Glessner
Pfizer, Inc.
As Vice President, Head of Clinical Trial Process and Quality (CTPQ), Coleen leads
Pfizer’s GCP quality management system to ensure that the portfolio of clinical
trials meets the highest standards of quality, compliance, and process excellence.
CTPQ is also accountable for processes and controls that include SOPs, training,
metrics and quality assessments. Most recently, she has been focused on building
quality into Pfizer’s partnerships and driving a culture of quality.
Rick Sax, M.D.
Quintiles
Dr. Sax is a >20-year veteran of the pharmaceutical industry, having held senior
positions in Clinical Development at Merck & Co. and AstraZeneca. His career
has included leading cardiovascular drug development at Merck, and leadership
roles in the U.S. Business, Global Medical Sciences, and New Opportunities
at AstraZeneca. Prior to joining Quintiles in 2011, he helped lead an effort at
AstraZeneca to transform Clinical Development, focusing on improving program
and protocol design. In his current role at Quintiles, he oversees the Biostatistics/
Medical Writing/Global Regulatory Affairs (Clinical Analysis & Reporting Services),
Safety Knowledge & Reporting, and the Center for Integrated Drug Development
– Quintiles home for clinical program and trial design and its enabling technology
platform, Infosario Design®.

Judy Swilley, Ph.D.
INC Research®
Judy Swilley, Ph.D. is an Executive Vice President and General Manager at INC
Research, where she has accountability for the company’s Strategic Alliance team
as well as the Global Clinical Operations Management group. Dr. Swilley has more
than 26 years of experience in the global CRO and pharmaceutical industry. She
has spent the past 21 years within global CROs including executive-level positions in
Strategic Partnership Development, Global Clinical Operations, Project Operations,
Clinical Monitoring and Staff Training and Development. Judy also spent over
5 years with Rhone-Poulenc Rorer (now Sanofi-Aventis) as a CRA and Clinical
Research Manager.
Judy graduated with a bachelor’s degree in Pharmacology from the University
of Liverpool in the United Kingdom, and completed a Ph.D. in Pharmacology at
Liverpool jointly with the Liverpool School of Tropical Medicine.

SUMMIT MODERATORS, FACILITATORS
AND FACULTY
DrugDev
Founder and Chief Commercial Officer, Melissa Easy is responsible for leading
DrugDev’s commercial strategy and development. Over the years, Melissa has
worked as a consultant for CROs both large and small and more pharmaceutical
companies than she dares count. The insight she accumulated in these roles, and
the inefficiencies and resulting frustrations she witnessed, laid the concept for
DrugDev. From its humble birth in 2009, Melissa is very proud of how her ‘first child’
has blossomed and DrugDev’s success to date in carrying out its mission of helping
sponsors and CROs identify, pay and engage investigators.
Melissa Easy
GUEST SPEAKERS
Jennifer Byrne
PMG Research
Jennifer Byrne, CEO of PMG Research, leads one of the largest Integrated Site
Networks in the U.S, which provides a comprehensive research infrastructure to
large multi-specialty physician, practices, healthcare institutions, academic centers,
and community based private practice physicians. Jennifer and her team of 150
Clinical Research Coordinators and support staff and 130 Principal Investigators
have conducted over 7,000 pharma and device trials with the inclusion of well over
100,000 trial participants. She is the founder of The Greater Gift Initiative, a non-
profit organization dedicated to honoring clinical research volunteers through the
gifting of lifesaving vaccines to children in developing countries. Jennifer serves
on the Advisory Board for CISCRP and the Wake Forest Institute for Regenerative
Medicine, and has served as Mentorship Committee Chair for the Society of Clinical
Research Sites. Jennifer was named to the CenterWatch Top 20 Industry Innovators
in 2013.

Jeremy Gilbert
PatientsLikeMe
Jeff James is the CEO of Wilmington Health in Wilmington, NC. He is responsible
for the strategic vision and its deployment as well as all financial and operational
aspects of the practice.
Jeff is a frequent national speaker on a diverse range of subjects including:
Lean/Process Improvement in Healthcare, Cultural Transformation, Aligning
Incentives and Physician Leadership. He is a physician advocate and healthcare
executive with over 18 years of strategic and operational experiences.
He has participated as an active Board Member on several community and
healthcare related organizations including: The American Medical Group
Association, Coastal Connect Health Information Exchange, the Economic
Development Corporation, Wilmington Chamber of Commerce and the North
Carolina State Medical Society’s ACO Steering Committee.
Jeff holds a Master of Business Administration Degree and is a Certified Public
Accountant.
Wilmington Health, PLLC
Jeff James
A seasoned business development and innovation professional with deep
experience navigating the healthcare value chain, Jeremy Gilbert leads product
strategy and development efforts at PatientsLikeMe. He is also responsible for the
company’s commercial products, which help pharmaceuticals, providers and others
in the healthcare industry better understand unmet patient needs. Prior to joining
PatientsLikeMe, Jeremy was an Engagement Manager at McKinsey & Company’s
healthcare practice, where he led strategy and execution projects for Fortune 500
clients. Jeremy has co-founded four technology startups and has invented and
launched notable products in e-commerce, mobile and discovery bioinformatics.
He is the creator of the Sapphire Biobanking Solution, a state-of-the-art informatics
platform that tracks biological materials and their genotypic and phenotypic data.
A true technologist, Jeremy has developed software since the age of seven and
spent more than 14,000 career hours in software design and construction. The
recipient of Boston Business Journal’s “MBA All Star Award,” Brandeis University’s
Michtom Prize for Excellence in Computer Science, and MIT’s Seley Scholar award,
Jeremy earned his bachelor’s degree in computer science and anthropology from
Brandeis University. He also holds a master’s degree in business administration from
MIT’s Sloan School of Management.
PANELISTS AND PRESENTERS GUEST SPEAKERS

Princeton Consultants, Inc.
Steve Sashihara is the co-founder and CEO of Princeton Consultants Inc., which
blends information technology and management consulting. Steve leads the firm’s
Custom Optimization practice—transforming businesses by designing and installing
software that makes tangible recommendations for action.
Steve is the author of “The Optimization Edge: Reinventing Decision Making to
Maximize All Your Company’s Assets” (McGraw Hill), the first non-technical book to
explain optimization to the busy business executive (www.optimizationedge.com).
It has been reviewed by publications such as Forbes, Investor’s Business Daily and
Consulting Magazine. In April 2012 Steve contributed the article, “From Big Data to
Big Optimization: What Every Executive Needs to Know,” to The European Financial
Review.
Steve graduated in 1980 from Princeton University. He serves on the advisory
council for the university’s department of Operations Research and Financial
Engineering (ORFE).
Steve Sashihara
GUEST SPEAKERS

The Avoca Group, Inc.
Debbie Briffa is Senior Project Manager of The Avoca Group. In this key role, Debbie
manages and oversees a variety of relationship programs for both our pharma
and CRO clients. In addition, Debbie is an active member of the Avoca Quality
Consortium leadership team working on a variety of projects including our recently
launched Pre Qualification initiative as well as managing our Quality Oversight
Portal, and overseeing the logistics for the Summit and other Consortium meetings.
Prior to joining Avoca, Debbie had over 16 years of executive and management
experience. She was former Vice President, Corporate Services and Marketing at
Morgan Stanley managing all of the Firm’s Corporate Service functions including
Procurement, Contingent Labor, Global Media Production, Business Services and
Marketing, and the Global Events Planning group.
Dr. Denise Calaprice-Whitty has extensive experience in directing clinical research
programs in a variety of settings including academia, a CRO, a large global
pharmaceutical company, and a small biotechnology company. After receiving
her Bachelor’s Degree in Biology from Harvard University and her M.S. and Ph.D.
from Princeton, Dr. Calaprice-Whitty entered the world of clinical research as
an NIH fellow at Columbia University’s College of Physicians and Surgeons. She
subsequently joined Quintiles as a Clinical Research Project and Program Director,
where she directed full- service international research programs including studies
in Phases I through IV, and including NDA and IND preparation, submission, and
support. As Senior Director of Clinical Research at Altana Pharma, Dr. Calaprice-
Whitty developed the infrastructure of the U.S. clinical research department and
contributed to infrastructure development internationally, including training of
personnel, SOP and guideline development, and KOL relationship development,
while simultaneously overseeing the performance of both outsourced and sponsor-
performed international clinical trials. As Director of Clinical Sciences at Regeneron
Pharmaceuticals, Dr. Calaprice-Whitty played a similar role, overseeing programs in
Phases I through III.
As a consultant for the last 10 years, Dr. Calaprice-Whitty has provided support to
pharmaceutical companies, clinical service providers, university investigators, and
government agencies engaged in clinical research, with a focus on the areas of
partnering strategies, relationship management, metric development, and business
data analysis. She also oversees the annual Avoca Industry Survey and Avoca
Quality Consortium Survey research programs.
Debbie Briffa
Denise Calaprice-Whitty, Ph.D.
AND FACULTY

AND FACULTY
AND FACULTY
Caryn Laermer is Associate Director of The Avoca Quality Consortium. In this key
role, Caryn manages and oversees all Consortium strategies and initiatives, member
engagement, member recruitment, member and industry communications and
Summit and other Consortium meetings.
Prior to joining Avoca, Caryn had several years of executive and management
experience. She was former Vice President, Derivatives Group at Donaldson, Lufkin
& Jenrette (now Credit Suisse) specializing in the sales and trading of stock options,
foreign currency derivatives and futures.
Ms. Laermer graduated from Tufts University with a B.A. in Economics. She is a
member of Omicron Delta Epsilon, Economics Honor Society and holds an MBA in
Finance from New York University.
Caryn Laermer, MBA
Janis L. Hall, MBA, COP
Janis Hall has over 25 years of experience in the healthcare industry with
leadership roles in pharmaceutical, biotechnology, CRO and medical diagnostic
companies. While at Johnson & Johnson Pharmaceutical Research & Development
(J&JPRD) she was responsible for R&D sourcing, contracting and supplier alliance
management. As the primary point of contact to health authorities for inspection
readiness for strategic sourcing, she developed and successfully implemented an
end-to-end process for inspection readiness of the sourcing organization.
Janis is a Certified Outsourcing Professional and has been a chair, invited speaker
and panelist at numerous conferences. She holds a MBA from the University of
Delaware and a BS in Chemistry from Towson University.

Taft and Partners
Pete Taft
In his 30-year career as a writer and communications executive, Pete Taft has
coached hundreds of business leaders, scientists, politicians, and public officials in
the art and science of persuasive communications. He is the Founder and CEO of
ClearPoint as well as two other successful communications firms: PharmApprove,
a regulatory communications consultancy to the pharmaceutical industry, and
Taft and Partners, an award-winning branding, marketing and public relations firm.
Pete began his career as a newspaper and magazine journalist in New York before
becoming the Communications Director for the New Jersey Department of Labor
and Industry, where he transformed the way that agency and its leaders spoke to
the public. As a result of that work, Pete was asked to serve as a communications
adviser to both the governor’s senior staff as well as his campaign communications
committee. He continues to coach political candidates, Congressional
representatives, and other elected officials as well as leaders in both the public
and private sector. Pete has delivered scores of workshops on communications
throughout the US and Europe and is much sought after as both a coach as
well as keynote speaker.
Patricia Leuchten is a leading authority on global clinical outsourcing and strategic
alliances between pharmaceutical sponsors and clinical research organizations
(CROs). Ms. Leuchten has more than 25 years of industry experience and founded
The Avoca Group in 1999. As the industry’s premier consulting and survey research
firm, The Avoca Group offers specific expertise in clinical outsourcing and alliance
management. In 2011, Ms. Leuchten founded the Avoca Quality Consortium,
a member-driven organization of 35 pharmaceutical and CRO companies,
bringing together Executives, Quality Management, Outsourcing and operational
professionals in the collaborative effort to accelerate the development of a best
practice approach to proactive quality management and CRO oversight.
Ms. Leuchten is a frequent speaker and writer on topics addressing clinical
outsourcing, strategic alliances, quality management, and relationship management
in the pharmaceutical industry.
Patricia Leuchten
AND FACULTY

Steven B. Whittaker
Steven B. Whittaker is Executive Director, for The Avoca Quality Consortium and
Senior Consultant for the Avoca Group, where he conducts Quality Workshops,
Executive Level Consulting for Pharmaceutical Quality, Clinical Development,
Project Management, Sourcing, Alliance and Relationship Management.
Steve’s wealth of experience through years of drug development leadership
roles and his established network with professionals across these industries
provide a unique and valuable combination of insights for organizational leaders.
Whittaker has served for 12 consecutive years on the Advisory Board for the annual
Partnerships in Clinical Trial program, chairing the board for 2 years. In addition,
Whittaker has moderated numerous quarterly Clinical Research Consortium forums,
developing strategic agendas and facilitating the exchange of leadership concepts
between clinical development executives across several top-tier pharmaceutical and
biotech organizations.
Whittaker retired from Eli Lilly and Company in December 2009 where he served
as Chief Operating Officer/Sr. Director of Operations and Project Management for
the Cardiovascular/Acute Care Platform. As the leader of the Global Clinical
Research Sourcing Office, Whittaker established Lilly’s first corporate strategy and
operational design for outsourcing global clinical development to CRO preferred
partners. This included the selection and initial implementation of the preferred
partner approach for global, full-service CRO capabilities. Whittaker also led Lilly’s
Project Management Center of Excellence, establishing standards for leaders of
project development.
AND FACULTY

THANK YOU TO OUR 2014 SUMMIT GOLD SPONSOR
ICON plc is a global provider of outsourced development services to the
pharmaceutical, biotechnology and medical device industries. The company
specialises in the strategic development, management and analysis of programs
that support clinical development - from compound selection to Phase I-IV
clinical studies. With headquarters in Dublin, Ireland, ICON currently, operates
from 76 locations in 37 countries and has approximately 10,300 employees.
Further information is available at www.iconplc.com.

THANK YOU TO OUR 2014 SUMMIT SILVER SPONSORS
Acurian is a leading full-service provider of clinical trial
patient enrollment and retention solutions for the life
sciences industry. The company increases the enrollment
performance of investigator sites worldwide by identifying,
contacting, prescreening, and referring people who live in
the local community but are unknown to a research site.
As a result, trial sponsors complete enrollment without
incurring the unexpected expense of adding sites, time, or
CRO change orders.
INC Research is a therapeutically focused contract research
organization with an unrivaled reputation for conducting
global clinical development programs of the highest
integrity. Pharmaceutical and biotechnology companies
look to INC Research for a complete range of customized
Phase 1 - Phase 4 programs in therapeutic areas of
specialty, and in innovative pediatric trials. Our “Trusted
Process™” methodology and therapeutic foresight leads
our customers to more confident, better-informed drug
and device development decisions. . For more information,
please visit our website at www.incresearch.com.
DrugDev streamlines engagement among sponsors,
CROs and doctors to advance the common goal of doing
more trials. Through the creation of global, standardized
processes, the use of smart technology, and the cultivation
of unique relationships DrugDev is consistently and
efficiently transforming the way drug developers identify,
engage and pay investigators.
inVentiv Health Clinical is a leading provider of global drug
development services to pharmaceutical, biotechnology,
generic drug, and medical device companies, offering
therapeutically specialized capabilities for Phase I–IV
clinical development, bioanalytical services, and strategic
resourcing from a single clinical professional to an entire
functional team. With 6,500 passionate employees
supporting clients in more than 70 countries, inVentiv
Health Clinical works to accelerate high quality drug
development programs of all sizes around the world.
www.inventivhealthclinical.com

2014 marks the 15th year The Avoca Group has been successfully helping
pharmaceutical, biotech and clinical research organizations build,
measure and manage critical business relationships.
As part of Avoca's 15th anniversary, we are donating $10,000 to support
the Pancreatic Cancer Action Network. This is in honor of friends and
family members who have been impacted by this devastating disease.
The Pancreatic Cancer Action Network is a nationwide network of
people dedicated to working together to advance research, support
patients and create hope for those affected by pancreatic cancer. Go to
www.pancan.org for more information.
“Being part of a clinical trial has shown me the difference between thinking
‘outside of the box’in terms of patient care and treatment, and accepting what
was essentially a hopeless diagnosis. My trial gave me the hope I needed to
face my fears.”
–Pancreatic cancer trial participant

ABOUT THE AVOCA GROUP
Founded in 1999, The Avoca Group is a consulting and survey research firm
based in Princeton, New Jersey. The Avoca Group develops and implements
global relationship and alliance management and quality oversight programs
for pharmaceutical companies, biotech companies, and pharmaceutical ser-
vice providers. Avoca works solely in the healthcare industry.
The Avoca Group
179 Nassau St.
Suite 3a
Princeton, NJ 08542
Phone (609) 252-9020
Fax (609) 252-9022
For information regarding new Membership for Avoca’s Quality Consortium,
please contact Danya Burakoff at
Danya.Burakoff@TheAvocaGroup.com or (619) 994-8677.
Existing Members, please contact Caryn Laermer at
Caryn.Laermer@TheAvocaGroup.com or (609) 799-0511.
© 2014 The Avoca Group
CONTACT US

Avoca Quality Consortium 2013 Summit Breaking Down Silos

Recommended

Recommended

More Related Content

What's hot

What's hot (20)

Similar to Avoca Quality Consortium 2013 Summit Breaking Down Silos

Similar to Avoca Quality Consortium 2013 Summit Breaking Down Silos (20)

More from The Avoca Group

More from The Avoca Group (20)

Recently uploaded

Recently uploaded (20)

Avoca Quality Consortium 2013 Summit Breaking Down Silos